Medical/Pharmaceuticals
DermRays Revolutionizing At-Home Laser Hair Removal with Innovative New Products
PLEASANTON, Calif., Nov. 11, 2024 /PRNewswire/ -- As anticipation grows around
DermRays' latest developments, industry insiders are abuzz with speculation
about the future direction of the company's product line. Whether through a
potential upgrade to theV8S Pro
2024-11-11 21:00
773
Economist Impact's 4th edition Future of Health Asia to empower healthcare stakeholders by building strategies for a sustainable healthcare system, and igniting investment for an inclusive and healthier future
Members of the media are invited to register here
2024-11-11 20:56
1768
Diabetes Singapore and GSK Join Forces to Spotlight Increased Risk of Viral Infections for People with Diabetes
* Diabetes Singapore and GSK aim to enhance awareness and improve lives affected by diabetes through educational talks and activities on World Diabetes Day * 1 in 3 people will get shingles in their lifetime; People with diabetes are 38% more likely to contract shingles[1] * People with dia...
2024-11-11 20:47
1245
Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for NUZ-001 in Europe
Highlights: * Notice of positive opinion received from the European Medicines Agency for Orphan Medicinal Product Designation for NUZ-001 in Amyotrophic Lateral Sclerosis * Orphan Designation offers 10 years of market exclusivity in Europe upon product approval, along with additional regulat...
2024-11-11 20:30
1006
ObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults
* Obese or overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of -11.15%, -13.22%, -14.25%, -17.29%, and -17.78%, respectively, with the placebo group at -0....
2024-11-11 19:36
1169
HKBN x INDICAID Introduce Hong Kong's First At-Home Health Test Monthly Subscription Service
HKBN further expands footprint in medical services HONG KONG, Nov. 11, 2024 /PRNewswire/ -- Hong Kong Broadband Network Limited ("HKBN") has partnered with renowned at-home health test brand, INDICAID, to provide HKBN customers with an innovative healthcare subscription service featuring a varie...
2024-11-11 16:06
1284
Nordic Bioscience receives Letter of Support from the FDA for the CPa9-HNE biomarker in inflammatory bowel diseases
HERLEV, Denmark, Nov. 11, 2024 /PRNewswire/ -- Nordic Bioscience, a leading
biomarker company, announced that its CPa9-HNE biomarker assay received a
Letter of Support (LoS) from the U.S. Food and Drug Administration (FDA).
2024-11-11 15:00
1093
GenScript Biotech Sets Up New Operations and Logistics Hub in Sydney, Australia
PISCATAWAY, N.J., Nov. 11, 2024 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript"), a global leader in life sciences services and products, has announced the establishment of new operations site and logistics center in Sydney, Australia. This strategic expansion represents a significant m...
2024-11-11 10:58
1486
TB Alliance Joins Indonesia's High-Level Meeting on TB
Announces Strategy to Accelerate Efforts Toward Ending the TB Pandemic BALI, Indonesia, Nov. 11, 2024 /PRNewswire/ -- TB Alliance is honored to join today's High-Level Meeting hosted by the Indonesian Ministry of Health. Leaders and experts in tuberculosis (TB) have convened to discuss strategies...
2024-11-11 10:30
1302
Late-Breaking Abstract! Alphamab Oncology Presented the Latest Clinical Data of Anti-HER2 bispecific ADC Subcutaneous Co-formulation JSKN033 at SITC 2024
SUZHOU, China, Nov. 11, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the results of the first-in-human clinical study of JSKN033, a high-concentration subcutaneous co-formulation consisting of anti-HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immune check...
2024-11-11 10:04
1348
Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology
DAEJEON, South Korea, Nov. 10, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteo...
2024-11-11 08:07
1231
Welcome to 2024 Chinese Congress of Holistic Integrative Oncology (2024 CCHIO)& 4th International Congress of the Asian Oncology Society (AOS2024)
XI'AN, China, Nov. 9, 2024 /PRNewswire/ -- On behalf of the organizing committee of the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO), we are very pleased to invite you to attend the 2024 CCHIO & 4th International Congress of the Asian Oncology Society (AOS2024) . This esteemed ...
2024-11-09 14:45
3491
HistoIndex to Present Latest Findings on AI-based Analysis using Stain-free Digital Pathology with 12 Accepted Abstracts at AASLD The Liver Meeting® 2024
SINGAPORE, Nov. 9, 2024 /PRNewswire/ -- HistoIndex, a pioneering leader in artificial intelligence (AI) and stain-free digital pathology, will present its latest research findings and advancements in AI-based analysis at the 75th The Liver Meeting® (TLM) 2024, hosted by the American Association f...
2024-11-09 02:00
4846
Henlius and SVAX Forge Strategic Partnership in the MENAT Market
SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- On the morning of November 7, at the 7th China International Import Expo (CIIE), Henlius (2696.HK) entered into a strategic collaboration with AL-TIRYAQ AL-KHALAWI Medical Company ("SVAX"), a subsidiary entity ofSaudi Arabia's prominent family business group...
2024-11-09 00:35
4088
Mabwell Reveals Encouraging Pre-clinical Data of 7MW4811 at the 15th World ADC Conference
SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, showcased the "Preclinical Development of 7MW4811, an Mtoxin™ (MF6)-based Antibody-drug Conjugate for the Treatment of Solid Tumors" as a poster presentation at the 15 t...
2024-11-08 22:00
2330
Lunit Shows Promise of AI in Predicting Immunotherapy Response for Rare Cancer Patients at SITC 2024
Study reveals potential of AI-powered tumor microenvironment assessment in predicting treatment outcomes in rare cancer patients receiving pembrolizumab SEOUL, South Korea, Nov. 8, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and t...
2024-11-08 22:00
2568
DND International Eye Hospital: Pioneering SMILE Pro Surgery & Leading the Trend of Refractive Surgery Tourism in Vietnam
HANOI, Vietnam, Nov. 8, 2024 /PRNewswire/ -- DND International Eye Hospital is the first facility inVietnam to implement SMILE Pro technology, an advanced FDA-approved eye refractive surgery method. It is also an ideal destination for international tourists seeking to combine travel with refracti...
2024-11-08 20:11
5836
Samsung Biologics earns ISO certifications in recognition of business excellence
* The company adds new ISO certification for compliance management and certified to updated standards for information and cloud security * Certifications recognize Samsung Biologics' commitment to operational excellence and demonstrates the company's reliability and integrity as a trusted CDM...
2024-11-08 20:00
1423
Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
The submission is supported by data from the pivotal WU-KONG1 Part B study, which featured in an oral session at the 2024 ASCO Annual Meeting Sunvozertinib is the world's first and only oral drug approved for NSCLC patients with EGFR exon20ins SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Dizal (SSE:68...
2024-11-08 18:01
1179
Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 8, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunolo...
2024-11-08 17:45
1090
Week's Top Stories
Most Reposted
Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 305 media titles]
2024-11-20 13:29Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 301 media titles]
2024-11-21 10:30Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 299 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8680
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5513
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
4990
Yingli Solar's Global Product Workshops Launched in Malaysia
2024-11-15 21:40
4738
